StreetAlpha.app
Home › Stocks › IBRX

ImmunityBio, Inc. (IBRX)

Healthcare
$6.26
▲ +4.68%
LAST CLOSE · NOV 17

ImmunityBio makes ANKTIVA, an approved bladder cancer treatment, and develops immune-based cancer therapies and vaccines. It last closed at $6.26 on Nov 17, up 4.68% on the day. The average 12-month price target from 2 analysts is $14.50 (+131.6% from the last close), with a high of $15.00 and a low of $14.00. Over the past 90 days StreetAlpha recorded 1 whale options trade in IBRX, 100% of them bullish and 0% bearish. In the past 30 days there were 8 dark pool prints totaling $4.2M, the largest $1.7M.

AI Auto Pilots
Is IBRX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$182.6M
+121.2% vs a year ago
Net income
−$1.1B
−607.8% margin
EPS (diluted)
−$1.06
Free cash flow
−$296.7M
−162.5% margin
Valuation
Market cap
$6.7B
1.06B shares
P/E
–
No P/E while losing money
Price to sales
36.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$45.1M
At Sep 30
Shareholder equity
−$1.1B
Shares outstanding
1.06B
At Nov 3
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $934K$934KFY2021FY2022: $240K$240KFY2022FY2023: $622K$622KFY2023FY2024: $14.7M$14.7MFY2024FY2025: $113.3M$113.3MFY2025

From IBRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.

Last report
Nov 9
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated IBRX in the past 90 days, not enough for a consensus
Average 12-month target
$14.50
▲ 131.6% upside

Based on 2 analysts who set a price target on IBRX in the past 90 days. The average target is $14.50, with a high of $15.00 and a low of $14.00, compared with the last close of $6.26.

$6$9$12$16PAST 107 TRADING DAYS12-MONTH TARGETSHIGH $15AVG $14.50LOW $14May 22LAST CLOSE+12 MO$6$9$12$16PAST 107 DAYSTARGETSHIGH $15AVG $14.50LOW $14May 22LAST CLOSE+12 MO
Highest target$15.00
Average target$14.50
Lowest target$14.00
Latest rating changes
JefferiesMaintained
Oct 15Buy$14
HC Wainwright & Co.Reiterated
Oct 15Buy$15
BTIGReiterated
May 21Buy$12
DateFirmActionRatingPrice target
Oct 15JefferiesMaintainedBuy$14
Oct 15HC Wainwright & Co.ReiteratedBuy$15
May 21BTIGReiteratedBuy$12
Loading…

Technical Analysis

IBRX · as of the Nov 17 close · updated after every close
Turning down, nearing oversold

The stock is 23% below its 20 day and 36% below its 50 day average. It is 27% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the Pivot at $6.24, and the nearest resistance the Pivot R1 at $6.40.

Short trendBearish
Long trendNeutral
MomentumWeak
StretchNear oversold
VolatilityHigh, 10.7%/day
Key levels
$12.4352 week high+98.6%
$8.5150 day average+35.9%
$8.19100 day average+30.8%
$7.97200 day average+27.3%
$7.7120 day average+23.2%
$7.62Swing high (Jul 31)+21.7%
$6.40Pivot R1+2.2%
$6.26Last close
$6.24Pivot−0.3%
$6.10Pivot S1−2.6%
$1.9552 week low−68.8%
Indicators
RSI (14)35.72Weak, oversold below 30Neutral
MACD-0.73Below its signal lineBearish
Stochastic9.6Near the bottom of its rangeOversold
ADX (14)25.9Trending down
Williams %R-84.3Oversold below −80, overbought above −20Oversold
CCI (20)-108.0Oversold below −100, overbought above 100Oversold
Rate of change−24.5%Change over 10 sessionsBearish
ATR (14)$0.67Typical daily range, 10.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IBRX

What happened before

See how IBRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow IBRX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How IBRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Sep 22 – Sep 22
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
8
Notional
$4.2M
Largest print
$1.7M
Loading…

IBRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲194 buying vs 150 selling
  • ●Held by funds +0.3 pts
  • ●Funds holding +0
  • ▼Superinvestors: 1 added, 2 cut
  • ▼Put/call 0.87 to 1.91
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding4064060.0%
In funds' top 1043+33.3%
Held by funds19.5%19.1%+0.3 pts
New / increased52 / 14259 / 139−2.0%
Reduced / sold out99 / 5199 / 44+4.9%
Put/call ratio1.910.87+120.5%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IBRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IBRX is in one of them and how their past IBRX trades turned out.

IBRX in the AI portfolios
Loading…

IBRX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IBRX in an article yet. Here's the latest on the wider market.

IBRX Congress Trades

All congress trades →
Trades, 12 months
2
Buys
2
100%
Sells
0
0%
People
1
Last filed Oct 12
Who traded IBRX · since 2023
Latest 3 filings
$1K – $15KTraded Sep 30, 2026Filed Oct 12, 2026
$1K – $15KTraded Sep 28, 2026Filed Oct 12, 2026
$1K – $15KTraded Mar 6, 2023Filed Apr 17, 2023
PersonTypeAmountTradedFiledDelay
Lisa McClainR · MIBuy$1K – $15KSep 30, 2026Oct 12, 202612 d
Lisa McClainR · MIBuy$1K – $15KSep 28, 2026Oct 12, 202614 d
Dan GoldmanD · NYSell$1K – $15KMar 6, 2023Apr 17, 202342 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About ImmunityBio

ImmunityBio is a biological products company based in San Diego, California. Its main approved product is ANKTIVA, a treatment for bladder cancer that it sells in the United States and through partners in other regions. The company is also developing cell therapies, cancer vaccines and other treatments that work through the immune system for cancer and infectious diseases.

Headquarters
San Diego, CA